A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions

NCT03905564 | Withdrawn Phase 1

• 3 other identifiers: HP8012-01DXLPRD-06-GRU17-CI-09 012 084
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of the study is to investigate any difference in the extent and rate of absorption of doxylamine between the test (investigational medicinal product \[IMP\]) and reference products that could impact the bioavailability of the medication when administered under fasting conditions.

Conditions

Bioavailability

Outcome Measures

Primary Outcomes (2)

• Area under the plasma concentration curve from the administration until the time t (AUC0-t) of doxylamine

  19 plasma samples will be collected from pre-dose to 48 hours post-dose. Doxylamine plasma concentrations will be determined using a high-performance liquid chromatography-tandem mass spectrometry bioanalytical assay.

  From pre-dose to 48 hours post-dose

• Maximum plasma concentration (Cmax) of doxylamine

  19 plasma samples will be collected from pre-dose to 48 hours post-dose. Doxylamine plasma concentrations will be determined using a high-performance liquid chromatography-tandem mass spectrometry bioanalytical assay.

  From pre-dose to 48 hours post-dose

Secondary Outcomes (2)

• Area under the plasma concentration curve from 0 to infinity (AUC0-inf) of doxylamine

  From pre-dose to 48 hours post-dose

• Time to maximum plasma concentration (Tmax) for doxylamine

  From pre-dose to 48 hours post-dose

Study Arms (2)

Doxylamine succinate/pyridoxine hydrochloride

EXPERIMENTAL

Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination) administered with 250 mL of water (at room temperature) under fasting conditions.

Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination

Diclegis (Registered Trademark)

ACTIVE COMPARATOR

Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg (i.e., 2 tablets) administered with 250 mL of water (at room temperature) under fasting conditions.

Drug: Diclegis (Registered Trademark)

Interventions

doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination DRUG

Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).

Doxylamine succinate/pyridoxine hydrochloride

Diclegis (Registered Trademark) DRUG

Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).

Diclegis (Registered Trademark)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participation will be voluntary and according to the guidelines proposed by the Health General Law and informed consent will be obtained according to the previously mentioned law. In addition, the study will be conducted according to the ethical principles that have their origin in the Declaration of Helsinki, the review of Brazilian laws, and Good Clinical Practice.
• Only healthy female participants aged between 18 and 55 years will be included.
• The body mass index must be between 18.0 and 27.0 kilograms per square meter according to the Quetelet index.
• Participants must be willing to use contraceptive methods (including barrier methods, non-hormonal intra-uterine device, or have a preexistent bilateral tubal ligation) during the conduct of the study and for up to 3 weeks after the last dose is administered.
• Participants must be healthy as determined by the results of a complete clinical history recorded by the clinical investigational site physicians and the results of the laboratory examinations and 12-lead electrocardiogram done by a certified clinical laboratory.
• The allowed limits of variation within normal in the screening visit will be: systolic blood pressure (sitting) less or equal to 120 mmHg, diastolic blood pressure less or equal to 80 mm Hg, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute according to the current standard operating procedure. Vital signs will be measured after 10 minutes of resting in a sitting position.
• Complete blood count: leukocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, erythrocyte distribution width, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils.
• Blood chemistry 27 elements: glucose, urea, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, uric acid, cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, low-density lipoprotein cholesterol, non-HDL cholesterol, atherogenic index, total protein, albumin, globulins, albumin/globulin ratio, total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, total alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase, iron, calcium, sodium, potassium, and chloride.
• Urinalysis: Physical examination (color, appearance, density); chemical examination (pH, leukocytes, nitrite, protein, glucose, ketones, bilirubin, urobilinogen, hemoglobin); microscopic examination (leukocytes, erythrocytes, dysmorphic erythrocytes, casts, crystals, squamous epithelial cells, tubular renal cells, mucus, bacteria and yeasts).
• Hepatitis B screening (Anti-HBc = Antibody to hepatitis B core antigen, HBs-Ab = antibody to hepatitis B surface antigen, Anti-HBs = antibody to hepatitis B surface antigen) and hepatitis C antibodies.
• HIV test: Antibodies to the human immunodeficiency virus (Anti-HIV 1 and 2).
• Venereal disease research laboratory (VDRL) test.
• Urine drugs of abuse test at the screening visit and at approximately 12 hours prior to the administration of the IMP in both study periods.
• Alcohol breath test approximately 12 hours prior to the administration of the IMP in both study periods.
• Serum pregnancy test (beta-human chorionic gonadotropin) at the screening visit and urine pregnancy test (qualitative) at approximately 12 hours prior to the administration of the IMP in both study periods.

You may not qualify if:

• Participants with a history of the following diseases: cardiovascular, renal, hepatic, muscular, metabolic, gastrointestinal, neurologic, psychiatric, hematopoietic, respiratory, urinary, or other organic abnormalities as well as those participants who have had muscular trauma within 21 days previous to the study will also be excluded.
• Participants who require any kind of medication during the course of the study, apart from the IMP.
• Participants with a history of dyspepsia, gastritis, esophagitis, duodenal, or gastric ulcer, pyloro-duodenal obstruction, asthma, and urinary bladder obstruction.
• Participants with angle-closure glaucoma.
• Current or recent (within 14 days prior to administration of the IMP) use of monoamine oxidase inhibitors (MAOIs).
• Participants who have been exposed to enzyme or hepatic inducers or inhibitors within 30 days previous to the start of the study.
• Participants who have taken any type of medication including vitamin supplements (with or without prescription) or herbal remedies (e.g., St John's wort) within 30 days (or 7 half-lives) previous to the start of the study.
• Participants who have been hospitalized for any reason within 6 months prior to the start of the study.
• Participants who have taken IMPs from other investigations within 90 days prior to study start.
• Participants with a history of allergy or hypersensitivity to the study medication (doxylamine/pyridoxine), any other medication, food, or substance.
• Participants who have consumed alcohol, carbonated beverages and/or or beverages that contain methylxanthines (coffee, tea, cocoa, chocolate, mate, cola, etc.), grapefruit juice, or charbroiled foods within 12 hours prior to the start of the hospitalization period as well as participants who have smoked tobacco within 12 hours prior to the study start.
• Participants who have donated or lost more than 450 milliliters of blood within 60 days prior to study start.
• Current or recent use of depressants of the central nervous system such as alcohol.
• Participants with a history of dependence/abuse of alcohol, psychoactive substances or chronic use of medications.
• Participants requiring a special diet for any reason, e.g., vegetarian.

Sponsors & Collaborators

• Grünenthal GmbH: lead
• Grünenthal, S.A.: collaborator

MeSH Terms

Interventions

doxylamine succinate; Pyridoxine; dicyclomine, doxylamine, pyridoxine drug combination

Intervention Hierarchy (Ancestors)

Vitamin B 6; Picolines; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Study Director

  Grünenthal GmbH

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Randomized, single-dose with two periods, two sequences (AB, BA; A = Reference and B = Test) crossover study in healthy participants under fasting conditions. Washout period between the two study periods will be at least 20 days.

Study Record Dates

• First Submitted: February 20, 2019
• First Posted: April 5, 2019
• Study Start: June 1, 2019
• Primary Completion: June 1, 2020
• Study Completion: June 1, 2020
• Last Updated: July 11, 2019

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will not share